Safety surveillance study reports baseline characteristics and preliminary safety in real-world Alzheimer’s treatment, suggesting valuable insights for clinical practice.
To report baseline characteristics and preliminary safety data from participants included in a multicenter, safety surveillance study of commercial lecanemab treatment for Alzheimer’s disease in real-world clinical practice using ALZ-NET registry.
No takes yet. Share an insight, caveat, or question.
Sabbagh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: